Using Polyethyline Oxide Blends to Assess the Effect of Excipient Variability - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Using Polyethyline Oxide Blends to Assess the Effect of Excipient Variability
The authors discuss a study that demonstrates the use of polyethylene oxide mixtures to investigate the effect of polymer viscosity on formulation robustness.


Pharmaceutical Technology
Volume 33, Issue 12


Table II: Weight-average and number-average molecular weight and polydispersity of polyethylene oxide (PEO) and PEO blends.
Weight-average molecular weight, number–average molecular weight, and polydispersity were determined by aqueous size-exclusion chromatography with a multiangle laser light-scattering (SEC-MALLS) detector. The SEC system consisted of a pump (Waters 2690 pump, Milford, MA), connected with a DAWN (MALLS) detector (Wyatt Technology, Santa Barbara, CA) and a Wyatt differential refractive index detector. The SEC fractionation of analyzed sample was evaluated to ensure an ideal SEC separation was obtained.


Figure 1: Differential weight fraction versus molar mass for Polyox 1105 water-soluble resin (WSR) samples and blend components, Polyox 205 NF WSR and Polyox N-12K WSR. (FIGURE COURTESY OF THE AUTHORS)
PEO samples were formulated into matrix tablets using theophylline and diltiazem HCl as model drugs. The formulations were comprised of the following by weight: 40% API; 30% polymer or polymer blend; 29.5% MCC; and 0.5% magnesium stearate. Tablets weighing 400 mg were prepared by direct compression using a 16-station tablet press (Manesty Beta,Knowsley, Merseyside, UK), equipped with 0.4063-in. (10.2-mm) flat-faced bevel-edge tooling at a compression force of 4000 lb (17.8 kN). Tablet hardness (n = 10) was measured with a hardness tester (Model HT-300, Key International, Englishtown, NJ). Drug dissolution was measured in a USP II apparatus (Varian/VanKel VK 7025, Varian, Palo Alto, CA) dissolution system with an ultraviolet–visible spectrophotometer, using three-prong capsule weights, in deionized water at 37.0 0.5 C, and a paddle speed of 50 rpm.

Results and discussion


Figure 2: Differential weight fraction versus molar mass for Polyox 1105 water-soluble resin samples and polyethylene oxide blends. (FIGURE COURTESY OF THE AUTHORS)
Effect of blending on viscosity. Table I compares the viscosity values for blended PEO samples to individual samples of Polyox 205 NF WSR, Polyox 1105 NF WSR, and Polyox N-12K NF WSR. Samples obtained of commercially available Polyox 1105 NF WSR only covered a narrow viscosity range of 9120–11,520 centipoise (cP) within the broader product-viscosity specification of 8800–17,600 cP. The lack of Polyox 1105 NF WSR samples with viscosities at the upper extremes of the product specification make it difficult to assess the impact of variability in product viscosity on drug- formulation properties. Thus, blends of Polyox 205 NF WSR and Polyox N-12K NF WSR were prepared in varying proportions to achieve a range of sample viscosities representative of Polyox 1105 NF WSR product viscosity. The viscosity results showed that blending of Polyox NF WSR product grades adjacent to the targeted Polyox product grade is a reasonable approach for obtaining representative Polyox NF WSR product viscosities for formulation testing.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here